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Abstract
The success of Imatinib (IM) therapy in chronic myeloid leukemia (CML) is compromised by the development of IM
resistance and by a limited IM effect on hematopoietic stem cells. Danusertib (formerly PHA-739358) is a potent pan-aurora
and ABL kinase inhibitor with activity against known BCR-ABL mutations, including T315I. Here, the individual contribution
of both signaling pathways to the therapeutic effect of Danusertib as well as mechanisms underlying the development of
resistance and, as a consequence, strategies to overcome resistance to Danusertib were investigated. Starting at low
concentrations, a dose-dependent inhibition of BCR-ABL activity was observed, whereas inhibition of aurora kinase activity
required higher concentrations, pointing to a therapeutic window between the two effects. Interestingly, the emergence of
resistant clones during Danusertib exposure in vitro occurred considerably less frequently than with comparable
concentrations of IM. In addition, Danusertib-resistant clones had no mutations in BCR-ABL or aurora kinase domains and
remained IM-sensitive. Overexpression of Abcg2 efflux transporter was identified and functionally validated as the
predominant mechanism of acquired Danusertib resistance in vitro. Finally, the combined treatment with IM and Danusertib
significantly reduced the emergence of drug resistance in vitro, raising hope that this drug combination may also achieve
more durable disease control in vivo.
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Introduction
Inhibition of BCR-ABL tyrosine kinase by Imatinib (IM, formerly
STI571, GleevecH) set new standards in the treatment of chronic
myeloid leukemia (CML). Indeed, durable hematological and
cytogenetic response can be achieved in the majority of patients
[1,2,3]. However, primary or acquired resistance to IM remains a
major therapeutic challenge in the course of CML treatment, in
particular in patients with advanced phase disease. Potential, yet
controversial, mechanisms of resistance comprise BCR-ABL gene
mutations, overexpression and amplification of the BCR-ABL gene
locus [4,5], activation of BCR-ABL independent pathways [6] or
increased drug efflux [7,8,9,10] as well as pharmacokinetic resistance
[11]. Mutations in the kinase domain of ABL, which either prevent
adoption of the inactive conformation required for IM binding or
directly interfere with inhibitor interaction, have been identified as
the predominant cause of relapse during IM therapy [12]. Second
generation tyrosine kinase inhibitors, such as Dasatinib [13],
Nilotinib [14] and Bosutinib [15,16], are capable of overcoming
the majority of resistance-conferring mutations clinically observed,
with the exception of the highly IM-resistant gatekeeper mutation
T315I. In addition, clinical observations as well as mathematical
modeling approaches suggest that IM controls rather than cures
CML [17,18,19,20]. We have shown that immature CML cells are
inherently insensitive to tyrosine kinase inhibitors, including IM [21],
Dasatinib [22], Nilotinib [23] and Bosutinib [24]. Furthermore,
persistence of minimal residual disease due to the limited effects of
tyrosine kinase inhibitors on immature (quiescent) hematopoietic
stem cells has been described [25]. Thus, the development of novel
therapeutic strategies is a major goal in the treatment of CML,
particularly in advanced stage and IM-resistant disease.
Recently, we reported on a novel small molecule inhibitor
Danusertib (formerly PHA-739358), which exhibits potent efficacy
against BCR-ABL and aurora kinases [26]. Anti-proliferative
activity was observed in human leukemia cell lines as well as in
CD34+ cells derived from newly diagnosed CML patients or IM-
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resistant individuals in chronic phase and blast crisis, including
those harboring a T315I mutation [27,28].
In this study, the individual contributions of BCR-ABL or
aurora kinase inhibition to the anti-proliferative effect of
Danusertib on Ph+ leukemic cells were analyzed. Particular
interest was devoted to investigating the mechanisms of Danu-
sertib resistance and the ability of combination therapy to prevent
or reduce emergence of resistant clones in vitro.
Results
Inhibition of both BCR-ABL and aurora kinase pathways
contributes to the effects of Danusertib
We previously demonstrated that Danusertib inhibits both,
aurora and ABL kinases, and induced anti-proliferative and pro-
apoptotic effects via combined inhibition of the two respective
pathways [27]. In order to further elucidate the particular
contribution of the inhibition of either signal transduction pathway
for the effect of Danusertib on BCR-ABL-positive cells, we treated
K562 cells with Danusertib or IM at concentrations ranging from
0.01 to 5 mM for 24 hours and analyzed changes in the
phosphorylation status of CrkL and histone H3-Ser10 (downstream
target of BCR-ABL and aurora kinase B, respectively). As shown in
Figure 1A, the use of Danusertib at the lowest, nanomolar
concentration already resulted in some degree of inhibition of
BCR-ABL activity. Gradually rising concentrations of Danusertib,
up to 0.16 mM, were associated with a slowly increasing number of
apoptotic cells. However, a marked reduction of CrkL phosphor-
ylation, with a pronounced loss of viability due to apoptosis, was
only observed for concentrations higher than 0.32 mM. Addition-
ally, significant inhibition of phosphorylation of histone H3-Ser10
under Danusertib treatment was observed only at concentrations
.0.32 mM when compared to P-CrkL (Figure 1B). However, for
higher concentrations (.1.25 mM) strong inhibition of phosphor-
ylation of CrkL and H3-Ser10 and a high degree of apoptosis were
seen (Figure 1C). Taken togeter, these data suggest that the pro-
apoptotic activity of Danusertib at lower concentrations is mainly
due to inhibition of BCR-ABL kinase, whereas at higher
concentrations inhibition of both BCR-ABL and aurora kinases
pathways contributes to the observed effects. IM treatment at the
lowest concentrations (0.01 and 0.04 mM) resulted in only slightly
decreased phosphorylation of CrkL with no induction of apoptosis.
However, starting from 0.16 mM strong inhibition of phosphory-
lation of CrkL with a more pronounced apoptosis was seen. A
concomitantly decreased phosphorylation of H3-Ser10 observed
under IM treatment may point to a predominant anti-proliferative
effect preceding apoptosis as phosphorylation of H3-Ser10 by
Aurora B is thought to be essential for chromatin condensation
during cell division, and as such widely used as a marker of mitosis.
Danusertib and IM synergize to induce apoptosis in
BCR-ABL-positive IM-sensitive cell lines
Simultaneous treatment with Danusertib and IM led to an
increased rate of apoptosis in Ba/F3-p210, in the low-grade IM-
resistant Ba/F3-M351Tmutant, and in K562 cells, when compared
to the single compounds. In contrast, no such effects were observed
in BCR-ABL-negative Ba/F3, Ba/F3 harboring the highly IM-
resistant T315I mutation, or in HL60 cells (Figure 2A–F).
Danusertib induces polyploidy and cell death in stem
and progenitor cells
Because of the known effects of Danusertib on aurora kinases
[27,29], additional cell cycle analysis was performed in CD34+ CML
cells. A dose-dependent effect of Danusertib on the cell cycle profile was
observed, resulting in an increase in polyploidy as well as a slightly
rising number of apoptotic and necrotic cells, indicated by a growing
subG1 peak (Figure S1). However, comparable to the findings of the
apoptosis studies, these changes were most pronounced only at
concentrations of Danusertib equal to or greater than 50 nM.
Effects of Danusertib on different populations of
hematopoietic stem and progenitor cells from CML
patients
To further elucidate the efficacy of Danusertib on the different
populations of hematopoietic stem and progenitor cells, hematopoi-
etic cells derived from CML and non-CML patients were separated
by a cell sorter into the following three subgroups: (1) CD34+382
cells, (2) CD34+38+ cells, and (3) CD34238+ cells, reflecting an
increasing differentiation status of the cells. Following sorting, all
three subgroups were treated with Danusertib, IM or a combination
of the two compounds and the numbers of viable cells were evaluated
by trypan blue exclusion assay. A significant reduction in the number
of viable cells was demonstrated in all treatment groups following
monotherapy with IM or Danusertib (Figure 3A–B). The combina-
tion of both drugs, however, significantly increased the observed
effect on viable cells only for CML (Figure 3A). This effect was not
limited to more differentiated cells, but was also detected in immature
CD34+382 cells (Figure 3A). As expected, no such additive effects
were found in non-CML cells (Figure 3B) used as control. However,
neither monotherapy with Danusertib (2 nM) nor IM (5 mM), nor the
combination therapy caused significant induction of apoptosis in
CD34238+, CD34+38+ or CD34+382 cells at the concentrations
administered (Figure 3C–D). The effect of Danusertib on quiescent
stem cells was then analysed in CFSE assays. CD34+ CML cells were
treated with Danusertib (2 and 10 nM), IM (1 and 5 mM) or a
combination of both compounds and viable cells were analysed.
Again, the combination of both drugs induced a significant additive
effect by reducing viable CD34+ cells. As described previously [30],
IM resulted in an accumulation of CFSEmax cells, without significant
induction of apoptosis, suggesting ineffective eradication of quiescent
stem cells. At low concentrations (2 and 10 nM), Danusertib did not
appear to significantly affect quiescent stem cells, either by
accumulation of CFSEmax cells or by induction of apoptosis (Figure 4).
Resistance to Danusertib is not mediated by mutations of
the target kinases
In order to generate a resistance profile for Danusertib, Ba/F3-
p210 cells were treated with varying concentrations of Danusertib
and IM, based on the assay published by von Bubnoff et al. [30].
In line with previous results, a dose-dependent development of
resistance was observed for IM (Figure 5A). At the IC50
concentration 0.6 mM, 100% of the clones developed resistance
in the course of long-term treatment (42d) in vitro. As expected, the
frequency of resistant clones decreased with increasing concen-
trations of IM. Thus, exposure to 2 and 4 mM resulted in only
47% and 7.3% resistant clones, respectively. At a concentration of
2 mM, sequence analysis of the ABL kinase revealed only 3 of 96
clones that did not carry a mutation, while at higher concentration
(e.g. 4 mM), mutations of the ABL kinase were detected in all 7
resistant clones. The mutational spectrum observed involved
mutations that had previously been detected in patients receiving
IM (e.g. Q252H, G250E, E316K, T315I), with the exception of
the rather predominant A424T mutation (Figure S2).
A similar dose-dependent pattern of emergence of resistant clones
was found for Danusertib. However, resistant clones occurred
considerably less frequently compared to IM. Moreover, and in
Abcg2 in Danusertib Resistance
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Figure 1. A–C: Contribution of BCR-ABL and aurora kinase inhibition to the pro-apoptotic effects of Danusertib. K562 cells were
incubated with the indicated concentrations of Danusertib or IM for 24 hours. Intracellular flow cytometry was used to determine the
phosphorylation status of well-known BCR-ABL and aurora kinase B downstream targets, CrkL (A) and histone H3-Ser10 (B), respectively. Induction of
apoptosis was measured as the percentage of cells positive for activated caspase-3 (C). Bars represent the average of two independent experiments
6 SD. Significance was determined using t-test.
doi:10.1371/journal.pone.0019164.g001
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Figure 2. A–F: Danusertib and IM synergize to induce apoptosis in BCR-ABL-positive IM-sensitive cell lines. K562 (A), Ba/F3-p210 (D) and
Ba/F3-M351T (E) cells were exposed to their respective IC50 concentrations of Danusertib (0.2, 0.4, and 0.5 mM, respectively), IM (0.2, 0.9, and 1.6 mM,
respectively) or both inhibitors. HL-60 cells (B) were treated with their Danusertib IC50 concentration (3.0 mM), IM IC50 concentration for K562 or both
whereas Ba/F3 (C) and Ba/F3-T315I (F) cells were exposed to their respective Danusertib IC50 concentrations (0.33 and 0.12 mM, respectively), IM IC50
concentration for Ba/F3-M351T (1.6 mM) or combination of both. After 24 hours cells were collected and the apoptotic fraction was assessed by flow
cytometry as the percentage of cells positive for active caspase-3. Values for untreated controls were subtracted from the respective samples. Bar
graphs represent mean % of positive cells of three experiments 6 S.D. Significance was determined using t-test.
doi:10.1371/journal.pone.0019164.g002
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contrast to IM, under a concentration of 2 mM of Danusertib (i.e.
56IC50) no resistant clones emerged and under 4 mM (i.e. 106IC50,)
literally one clone was detected over 42 days of treatment. Interestingly,
sequence analysis of either BCR-ABL kinase or the coding sequences of
aurora kinases A and B, did not reveal any mutations.
Resistance to Danusertib is not associated with cross
resistance to IM
To evaluate a possible cross resistance of Danusertib-resistant clones
to IM, anti-proliferative activity of both compounds was analysed by
MTT assay. As expected, a substantial increase of the IC50 values was
observed for Danusertib (Table 1). However, IC50 of IM was not
elevated suggesting a preserved sensitivity of the Danusertib-resistant
cells for this tyrosine kinase inhibitor. In pharmacodynamic studies,
BCR-ABL activity was assessed via the phosphorylation status of CrkL.
For two clones showing a low-level of resistance for Danusertib (IC50:
2.1 and 2.8 mM, respectively) a reduced inhibition of P-CrkL was
found when compared to Danusertib-sensitive cells. CrkL remained
completely phosphorylated after treatment with Danusertib in highly
resistant clones (IC50: 13.4 and 45 mM). In comparison, exposure to
IM at a concentration of 5 mM led to the typical inhibition of P-CrkL
in all clones analyzed suggesting effective inhibition of BCR-ABL
kinase activity by this compound (Figure S3A–D).
Interestingly, inhibition of the phosphorylation of histone H3-
Ser10 was minimal in one of two low-level resistant clones compared
to non-resistant cells and was virtually absent in other clones tested
indicating an almost complete lack of Danusertib inhibitory effects on
these serine/threonine kinases in resistant cells (data not shown).
Combination therapy with Danusertib and IM
considerably decreases the development of resistant
clones in vitro
Next, the therapeutic impact of combination therapy with
Danusertib and IM on BCR-ABL-positive cells was evaluated.
Simultaneous use of both inhibitors considerably decreased the
emergence of resistant clones in a dose-dependent manner. Thus,
Figure 3. A–D: Danusertib is anti-proliferative against stem and progenitor cells independent of their differentiation or BCR-ABL
status. CML and normal CD34+382 primitive and CD34+38+ or CD34238+ committed progenitors were exposed to IM (light grey), Danusertib (dark
grey) or to the combination of both drugs (black) at indicated concentrations for 72 hours in relation to the control (white). Cell viability was assessed
by trypan blue exclusion assay (A–B) and apoptosis was analyzed by FACS as the percentage of cells positive for active caspase-3 (C–D). The effects of
Danusertib and IM on the viability of immature and committed CD34+ CML cells were found to be more pronounced for the drug combination (A).
After treatment, small percentages (non significant) of active caspase-3 positive cells, in both BCR-ABL-positive and negative cells, were observed in
the most committed fraction CD34238+ (C–D). For the intermediate fraction, CD34+38+, a similar effect was seen for CML (C), but not for non-CML
cells (D). No apoptosis was seen in the immature populations of either CML or non-CML cells. Results represent the mean 6 S.D. of replicate
experiments (n = 2) and asterices indicate p,0.05. Significance was determined using t-test.
doi:10.1371/journal.pone.0019164.g003
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a combination of IM and Danusertib at their IC50 concentrations
lowered the appearance of resistance to 27%, while in comparison,
control cells treated with IC50 of either IM or Danusertib
monotherapy, frequencies of 100 and 98% were observed,
respectively. Remarkably, at the 2-fold IC50 concentration of
Danusertib with IM at its IC50, a complete cell growth arrest was
observed and no resistant clones were detected at the end of the
experiment at day 42 (Figure 5A).
Analysis of Microarray data reveals overexpression of
Abcg2, a member of the ATP-binding cassette (ABC)
superfamily, as a potential cause of Danusertib resistance
In order to screen for genes that might be involved in the
emergence of Danusertib resistance, we hybridized samples from 2
resistant clones with the highest IC50 values and from parental cells
onto Affymetrix GeneChipHMouse Genome 430A 2.0 arrays. The
statistical analysis of Microarray data allowed the identification of
138 and 181 differentially expressed genes in the first (0.8–2; IC50:
13.4 mM) and the second (4.0–1; IC50: 45 mM) resistant clone,
respectively, as compared to the parental cells (Ba/F3-p210) with 95
genes common to both clones. Among them, Abcg2 gene was found
to be about 1000-fold overexpressed in the resistant clones tested
(Table 2). No other members of any transporter family were found
significantly overexpressed and no other specific function was
significantly affected. In view of these data, we examined the mRNA
expression level of Abcg2 in all Danusertib-resistant clones. High
Abcg2 overexpression was detected in all but one of the resistant
clones analyzed by RT-PCR and in all but two of the resistant
clones by Western blotting (Figure 5B–C). Thus, the observed
Abcg2 up-regulation might account for the emergence of resistance
under treatment with Danusertib.
Pharmacological inhibition of Abcg2 altered the
sensitivity of Danusertib-resistant clones
Given the hypothesis that Abcg2 overexpression is responsible for
resistance to Danusertib, we investigated whether the inhibition of
Abcg2 activity with its specific inhibitor FTC was able to restore the
effects of Danusertib treatment in vitro. Indeed, the cotreatment
with FTC strongly enhanced the pro-apoptotic effects of Danusertib
in resistant, Abcg2-overexpressing clones, whereas no such effects
were seen in the single resistant Abcg2-negative clone (Figure 6A–
C). Next, we evaluated the efficacy of Danusertib to inhibit BCR-
ABL mediated phosphorylation of the downstream target CrkL in
resistant clones cotreated with FTC. As shown in Figure 6D, Abcg2-
overexpressing clones showed little or no changes in phosphoryla-
tion status of CrkL upon treatment with Danusertib alone whereas
pronounced inhibition of CrkL-phosphorylation was observed in
cells cotreated with FTC. As expected, no such effects were
observed in Abcg2-negative control cells.
Overexpression of Abcg2 in parental Ba/F3-p210 cells
results in resistance to Danusertib
In order to further validate that Danusertib is a substrate of the
Abcg2 transporter, the effects of Danusertib treatment on cellular
proliferation were evaluated in Ba/F3-p210 cells retrovirally
transduced with Abcg2 or with control vector. The data from
MTT assay clearly demonstrate that in cells overexpressing Abcg2,
the IC50 for Danusertib was increased ,4.5 fold as compared to
control cells (IC50 values: 3.07 and 0.66 mM, respectively). In a
short-term proliferation assay (48 hours) a strong dose-dependent
reduction of cell growth was seen in control cells, whereas Abcg2-
overexpressing cells were significantly less sensitive to Danusertib
treatment (Figure 7). Again, this resistance-mediating effect of
Figure 4. Cell division tracking using CFSE assay. Assessment of CD34 expression or active caspase-3 expression versus CFSE fluorescence
remaining in cells following 72 hours of in vitro treatment with 5GF alone, 5 mM IM, 10 nM Danusertib and 5 mM IM+10 nM Danusertib. The boxes
shown indicate undivided cells (CD34+, CFSEmax) and the numbers represent the percent of total viable cells in this gate.
doi:10.1371/journal.pone.0019164.g004
Abcg2 in Danusertib Resistance
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Abcg2 overexpression was almost completely abrogated when the
cells were cotreated with FTC (Figure 7). Taken together, our data
show that Danusertib is a substrate of the Abcg2 transporter and
that overexpression of this efflux pump results in resistance to
Danusertib which could be abrogated by the pharmacological
inhibition of Abcg2 activity.
Discussion
Danusertib, formerly PHA-739358, is a small molecule 3-
aminopyrazole derivative which exhibits strong activity against all
members of the aurora kinase family, as well as against ABL kinase
[27,29]. In crystallographic studies, Danusertib binds to an active
Figure 5. A–B: Danusertib induced Abcg2 overexpression in resistant clones and combination of Danusertib with IM reduces the
frequency of resistant clones. (A) Ba/F3-p210 cells were cultured with graded concentrations of Danusertib or IM alone and in combination. Bars
represent the percentage of wells from which drug-resistant clones were recovered. A total of 96 wells were analyzed in all experiments except those
involving 0.8, 2, and 4 mM Danusertib as a single drug for which 144 wells were examined. (B) Abcg2 is overexpressed in all but one Danusertib-
resistant clones. Semi-quantitative RT-PCR analysis for Abcg2 mRNA level in Danusertib-resistant clones and parental Ba/F3-p210 cells. (C) Abcg2 is
overexpressed in all but two Danusertib-resistant clones. Western blotting analysis for Abcg2 level in Danusertib-resistant clones and parental Ba/F3-
p210 cells. The relative expressions in comparison to GAPDH are indicated.
doi:10.1371/journal.pone.0019164.g005
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conformation of the ABL kinase domain in the ATP-binding pocket
[28]. Remarkably, Danusertib lacks the steric hindrance imposed by
the substitution of threonine by isoleucine at position 315 and is
therefore likely to overcome the highly IM resistance conferring T315I
mutation. Indeed, we recently demonstrated that this inhibitor
effectively targets wild type and mutant BCR-ABL positive cells,
including the T315I mutation, in vitro [26] and in vivo [31]. Thus,
Danusertib represents a promising new treatment option for patients
suffering from IM-resistant CML and a phase II clinical trial, including
CML patients in accelerated phase or blast crisis harboring the T315I
mutation, is currently ongoing (NCT00335868, www.clinicaltrial.gov).
The aim of our study was to further characterize Danusertib
with regard to its predominant mode of action (inhibition of BCR-
ABL vs. aurora kinases) and its effects on the quiescent CD34+382
hematopoietic stem cell subpopulation. In addition, particular
focus was put on the potential development and underlying
mechanism of resistance to Danusertib including the investigation
of strategies suitable to overcome this problem.
First, in order to dissect the individual contribution of aurora
and ABL kinase inhibition to the effect of Danusertib, changes in
phosphorylation status of the BCR-ABL downstream target CrkL
and the aurora kinase downstream target histone H3-Ser10 were
analyzed. Exposure to Danusertib or IM at nanomolar concen-
trations resulted in inhibition of BCR-ABL activity. In compar-
ison, inhibition of histone H3-Ser10 phosphorylation seemed to
require higher amounts of Danusertib when compared to P-CrkL
and distinct effects on the phosphorylation status were only
observed at concentrations exceeding ,0.16 mM. The inhibition
of the BCR-ABL pathway seems to be the predominant effect of
Danusertib in BCR-ABL positive cells in vitro, at least at low
nanomolar concentrations.
These findings were further supported by cell cycle analysis. In
line with the known effects of Danusertib on aurora kinases
[27,29], dose-dependent changes of the cell cycle profile were
detected, reflected by increasing endoreduplication in both BCR-
ABL-positive and negative CD34+ cells. However, these changes
were only found at Danusertib concentrations exceeding 50 nM.
Thus, we postulate that side effects due to aurora kinase inhibition
in BCR-ABL-negative cells appear at higher dose levels, while in
contrast, inhibition of proliferation and induction of apoptosis in
BCR-ABL-positive cells can be achieved in the low nanomolar
range, which might potentially result in an therapeutic index
particularly for the treatment of highly IM-resistant BCR-ABL
mutants such as T315I.
Preliminary findings from human and murine cell lines had
pointed to a synergistic activity of Danusertib and IM [27].
Indeed, simultaneous treatment with Danusertib and IM resulted
in pronounced apoptosis in K562, Ba/F3-p210, and Ba/F3 cells
harboring the low-grade IM-resistant M351T mutation as
compared to monotherapy. In contrast, no such effects were
observed in BCR-ABL-negative cells or cells harboring the highly
IM-resistant T315I mutation. In addition, the additive anti-
proliferative activity of Danusertib and IM was also found in
primary CD34+ cells derived from CML patients, including the
immature CD34+382 subpopulation which has been demonstrat-
ed to contain quiescent leukemic stem cells [32,33].
In order to achieve cure of CML, the effective eradication of
minimal residual disease (e.g. quiescent CML stem cells) remains
an urgent treatment goal. However, neither IM nor second
generation tyrosine kinase inhibitors such as Dasatinib, Nilotinib
Table 1. IC50 of Danusertib-resistant Ba/F3-p210 cells after
long-term incubation with 0.8 mM (10 clones) or 4 mM (1
clone) of the inhibitor.
Clones and cell lines IC50 Imatinib (mM) IC50 Danusertib (mM)
0.8-1 0.9 2.1
0.8-2 0.6 13.4
0.8-3 0.8 2.8
0.8-4 0.3 1.1
0.8-5 0.3 2
0.8-6 0.5 1.2
0.8-7 0.7 1.2
0.8-8 0.6 1.2
0.8-9 1.2 5.3
0.8-10 0.8 9.5
4.0-1 1.6 45
Ba/F3-p210 0.6 0.4
Ba/F3 13.4 0.5
doi:10.1371/journal.pone.0019164.t001
Table 2. The top 10 up-regulated genes with the corresponding LogRatio values. In bold genes up-regulated in both analyzed
clones.
Clone 0.8-2 Danusertib IC50: 13.4m mM Clone 4.0-1 Danusertib IC50: 45 mM
Genes names Exp. Value Genes names Exp. Value
Abcg2 10.0 Abcg2 10.0
GSTK1 2.7 COL5A1 3.4
KEL 2.5 CTTN 3.0
PIP 2.2 KEL 2.3
TSC22D1 2.0 F10 2.2
CD244 2.0 TSC22D1 2.0
COL5A1 2.0 MUC20 2.0
SERPINF1 2.0 CXCR4 1.9
F10 1.9 C10ORF54 1.8
ACSS1 1.6 ITPR2 1.8
doi:10.1371/journal.pone.0019164.t002
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or Bosutinib has so far been demonstrated to effectively induce
apoptosis in the quiescent stem cell compartment [34,35].
Insufficient drug concentrations due to an imbalance between
drug influx and efflux [34,35], gene amplification [4], increase of
activity of BCR-ABL downstream effector kinases or high BCR-
ABL transcripts have been discussed as possible mechanisms
[36,37]. Indeed, the number of BCR-ABL copies and transcript
levels were found to be significantly higher within CD34+382
CML cells suggesting an increased activity of the BCR-ABL
protein in this cell subpopulation [22]. In line with previous
findings, we did not observe a loss of cell viability in stem or
progenitor cells treated with IM. Furthermore, and in contrast to
the proliferation experiments, neither Danusertib alone nor in
combination with IM was capable of inducing significant apoptosis
in the stem cell compartment when administered at low
nanomolar concentrations. In line with this finding, Danusertib
did not affect quiescent stem cells in CFSE assays in vitro. These
results point to a pronounced anti-proliferative effect, but do not
support significant activity towards eradication of quiescent and/
or minimal residual disease.
Occurrence of resistance secondary to treatment with tyrosine
kinase inhibitors complicates treatment of CML and is the major
cause of disease relapse in the course of therapy. In order to
generate a possible resistance profile, Ba/F3-p210 cells were
treated with varying concentrations of Danusertib or IM.
Confirming previous results, a dose-dependent development of
resistance was observed for IM with a mutational spectrum similar
to mutations observed clinically with the exception of the rather
predominat A424T mutation which, to our knowledge, has not
been described so far. Similarly, treatment with Danusertib caused
resistance in a dose-dependent manner however, resistant clones
occurred considerably less frequently than with IM treatment. In
support of these data, clones showing low-level resistance to
Danusertib exhibited a strong inhibition of phosphorylation of the
downstream target CrkL but interestingly, only minimal inhibition
of histone H3-Ser10 phosphorylation under Danusertib treatment.
In highly resistant clones, CrkL and histone H3-Ser10 remained
completely phosphorylated, indicating loss of efficacy of Danu-
sertib against both BCR-ABL and aurora kinases. Remarkably, all
Danusertib-resistant cells remained IM-sensitive as indicated by
MTT assays as well as by preservation of inhibition of CrkL-
phosphorylation under IM. Furthermore, sequence analysis of
BCR-ABL kinase domain and the coding sequences of aurora
kinases A and B, revealed no mutations and therefore was
eliminated as a possible mechanism of Danusertib resistance.
These findings strongly pointed to a common mechanism
underlying resistance to Danusertib in Ba/F3-p210 cells indepen-
dent of the individual target kinases. Analysis of data from
microarray gene expression profiling of resistant clones and
biochemical functional assays revealed that overexpression of the
Abcg2 efflux transporter protein was responsible for the
emergence of resistance under Danusertib treatment in 10 out of
Figure 6. A–D: The Abcg2 inhibitor FTC overrides Danusertib resistance. Danusertib-resistant cells from two Abcg2-positive (A and B) and
one Abcg2-negative (C) clones were exposed to indicated concentrations of Danusertib in the presence (black bar) or absence (white bar) of 5 mM
FTC for 24 hours. The effects on induction of apoptosis were measured by active caspase-3 assay. Intracellular flow cytometric analysis was used to
determine CrkL phosphorylation status (D). Results represent the mean 6 S.D. of replicate experiments (n = 2) and asterices indicate p,0.05.
Significance was determined using t-test.
doi:10.1371/journal.pone.0019164.g006
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11 clones. The functional relevance of these findings was strongly
supported by studies using the pharmacological Abcg2-inhibitor
FTC. Indeed, clones resistant to Danusertib and overexpressing
Abcg2 became sensitive to drug again once cotreated with FTC
whereas this was not the case in the single resistant clone which did
not overexpress Abcg2. Furthermore, retroviral overexpression of
Abcg2 in BCR-ABL-expressing Ba/F3 cells lead to resistance of
the cells to Danusertib which in turn, could again be reversed by
cotreatment with FTC. Taken together theses findings suggest a
central role of drug efflux out of BCR-ABL+ cells mediated by
Abcg2 overexpression as the mechanism of resistance to
Danusertib.
In view of the diverse and non-overlapping mechanisms of
resistance found for Danusertib as opposed to IM, the impact of a
combination therapy of both compounds was addressed in long-
term expansion culture. Simultaneous administration of both
inhibitors considerably decreased occurrence of resistance in a
dose-dependent manner. Noteworthy, at the twofold IC50
concentration of Danusertib combined with IM at IC50,
development of resistance could be prevented altogether.
In conclusion, Danusertib potently inhibits proliferation of
BCR-ABL-positive CD34+ stem and progenitor cells including
the immature CD34+382 subpopulation. However, similarly to
other tyrosine kinase inhibitors, no induction of apoptosis in
quiescent hematopoietic stem cells could be achieved under
Danusertib in vitro. Resistant BCR-ABL-positive clones emerged
in the course of Danusertib treatment and the predominant
mechanism of Danusertib resistance was overexpression of
Abcg2, which could be effectively overcome by pharmacological
inhibition of the activity of this efflux transporter. Furthermore,
Danusertib-resistant clones retained full sensitivity to IM and
the combination of Danusertib and IM successfully prevented
emergence of resistant clones altogether. These results suggest
that Danusertib is a substrate for the Abcg2 drug transporter.
With regards to the known inhibitory effects of IM on Abcg2,
our studies suggest that the additive effects of Danusertib and
IM on the emergence of resistant clones in vitro and on
proliferation of primary CML stem and progenitor cells can
be based on the accumulation of Danusertib in Abcg2
expressing cells [10]. Recent in vitro studies from Hiwase et
al. have identified a similar mechanism for the combination of
Nilotinib and Dasatinib in CML cells overexpressing the Abcb1
efflux protein [38].
Thus, these results represent a strong rationale for follow-up
studies addressing combination therapies of Danusertib with IM
and potentially, 2nd generation tyrosine kinase inhibitors such as
Nilotinib, Dasatinib and Bosutinib in order to improve therapeutic
effects in BCR-ABL-positive leukemias.
Materials and Methods
Reagents
IM was purchased from Toronto Research Chemicals Inc,
Ontario, Canada. Danusertib (formerly PHA-739358) was ob-
tained from Nerviano (Milan, Italy). Stock solutions of IM (10 mg/
mL; in DMSO/H2O (1:1)) and Danusertib (10 mM; in DMSO)
were stored at220uC. Fumitremorgin C (FTC) was obtained from
Alexis Biochemicals, San Diego, CA, USA and prepared as a
5 mM stock solution in DMSO.
Cell culture techniques
Human cell lines K562, HL60, and murine Ba/F3 were
obtained from DSMZ (Bielefeld, Germany). Ba/F3-p210,
-M351T, and -T315I cells were obtained from N.P. Shah and
C.L. Sawyers (UCLA, USA). All cell lines were cultured under
standard conditions as previously described [27].
Figure 7. Retroviral overexpression of Abcg2 altered the sensitivity to Danusertib. Overexpression of Abcg2 in parental Ba/F3-p210 cells
protects them against cytotoxic effects of Danusertib treatment. Ba/F3-p210 cells transduced with Abcg2 or with control empty vector were exposed
for 48 hours to the indicated concentrations of Danusertib. In addition, the Abcg2-overexpressing Ba/F3-p210 cells were treated in the same way in
the presence or absence of 5 mM FTC, a specific inhibitor of Abcg2 activity. In all experiments the number of viable cells was analyzed with Vi-CELL
XR. Bar graphs represent the mean of three (empty vector and Abcg2) or six (Abcg2+5 mM FTC) experiments 6 S.D. and asterices indicate p,0.05.
Significance was determined using t-test.
doi:10.1371/journal.pone.0019164.g007
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Isolation of CD34+ cells and their subpopulations
Fresh leukapheresis or peripheral blood samples were obtained
with written informed consent and approval of North Glasgow
University Hospital Division of NHS Greater Glasgow Institution
Review Board from patients with newly diagnosed chronic phase
CML (n= 4) and normal donors of peripheral blood stem cells
(n = 2). Samples were enriched for CD34+ cells using CliniMACS
(Miltenyi Biotec, Auburn, CA). CD34+ cells were expanded in vitro
as described previously [22].
Mutagenesis screen
Ba/F3-p210 cells were cultured in 24-well plates at a density of
16105 cells per well in the presence of 0.6, 2 and 4 mM IM or 0.4,
0.8, 2 and 4 mM Danusertib. For the combination assays, IM was
used at a fixed concentration of 0.6 mM with 0.4 or 0.8 mM
Danusertib. Single colonies growing out on the bottom of wells
were expanded for further analysis in the presence of inhibitor at
the concentration corresponding to that used in the screen. To
identify possible mutations in aurora kinase A and B domains, the
coding cDNAs of both enzymes were sequenced using the
following primers: auroraA1-fwd 59-AGGTTCCTGCCTGT-
GAGTTG-39; auroraA1-rev 59-GCTCATTCTTCTGGGGG-
TTA-39; auroraA2-fwd 59-GCAGATTCCGTCTCAGAACC-39;
auroraA2-rev 59-GCTGTTCTCTGCTCGTCAAA-39; aurora-
A3-fwd 59-GAGAGGTGGAGATCCAGTCG -39; auroraA3-rev
59-TGCATGGCCAAGGACTAGTT-39; auroraB1-fwd 59-CCT-
CTGCATCTCTTGCCTTC-39; auroraB1-rev 59-CTCCCTG-
CAGACCTAACAGC-39, auroraB2-fwd 59-CCTGAAACATCC-
CAACATCC-39, and auroraB2-rev 59- TTCCCACCCCTTCT-
CAGAAC-39. Sequencing of the ABL kinase domain was
performed as previously described [31]. For all RT-PCR
reactions, total RNA was isolated using TRIzol (Invitrogen).
cDNA was prepared by reverse transcription of 250 ng RNA with
oligo(dT)15 and Superscript II reverse transcriptase (Invitrogen)
and amplified using REDTaqTM ReadyMixTM PCR Reaction
Mix (Sigma-Aldrich).
RNA isolation and measurement of Abcg2 transcripts by
semiquantitative RT-PCR
RNA was isolated from the different cell clones using TRIzolH
reagent (Invitrogen, Karlsruhe, Germany) according to the
manufacturers’ protocol. The cDNA was prepared by reverse
transcription of 1 mg total RNA using oligo dT primer (15mer) and
M-MLV reverse transcriptase (Fermentas Life Sciences GmbH,
Germany). The PCR for Abcg2 and for the RPLP0 housekeeping
genes were performed as follow: 1 cycle of 94uC for 4 min and 30
cycles of 94uC for 30 s, 58uC for 1 min and 72uC for 1 min. For
amplification following primer pairs were used: for Abcg2 -
mAbcg2-fw: 59 -TCG CAG AAG GAG ATG TGT TG- 39 and
mAbcg2-rev: 59 –TTG GAT CTT TCC TTG CTG CT- 39
which gives a 204-bp product and for RPLP0 - RPLP0-fw: 59 -
TTG TGT TCA CCA AGG AGG AC- 39 and RPLP0-rev: 59 -
GAC TCT TCC TTG GCT TCA AC- 39 which gives a 649-bp
product.
Western Blotimg
Protein extracts were separated by 12% SDS-PAGE and
electrophoretically transferred onto PVDF membrane. Blocking
was carried out in 16Rotiblock solution (Carl Roth, Karlsruhe,
Germany) followed by incubating the membrane with anti-Abcg2
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and anti-
GAPDH antibody (Millipore, Billerica, MA) overnight at 4uC.
Excess antibodies were removed by washing with NaCl–Tris–
Tween 20. Incubation with secondary antibody conjugated to
horseradish peroxidase [anti-(mouse IgG) or anti-(rabbit IgG),
diluted 1:5000 in 16Rotiblock] was performed for 1 h at room
temperature. After three washes, the reaction was developed by
the addition of SuperSignal West Pico Chemiluminescent
Substrate (Thermo Fisher Scientific, Rockford, IL). The emitted
light was captured on X-ray film (GE Healthcare, Uppsala,
Sweden). Relative expression of Abcg2 was estimated using
Quantity One software (Bio-Rad Laboratories, Hercules, CA).
Short-term proliferation and MTT assay
For a short-term (48 hours) proliferation assay, cells were
collected and analyzed by Vi-CELL XR (Beckman Coulter,
Krefeld, Germany) according to the manufacturer’s recommen-
dation. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay was performed as previously described [39].
Intracellular flow cytometry
Assessment of protein expression level or phosphorylation status
of Crkl and histone H3-Ser10 by intracellular flow cytometry was
performed as described elsewhere [27].
Analysis of apoptosis by flow cytometry
K562, Ba/F3-p210 and Ba/F3-M351T cells were plated in
triplicates and exposed to their IC50 concentrations for Danusertib
(0.2, 0.4, and 0.5 mM, respectively), IM (0.2, 0.9, and 1.6 mM,
respectively) or both inhibitors, whereas HL-60, Ba/F3, and Ba/
F3-T315I cells were treated with their respective Danusertib IC50
concentrations (3.0, 0.33, and 0.12 mM, respectively), IM IC50
concentration for K562 (HL-60) and for Ba/F3-M351T (Ba/F3
and Ba/F3-T315I) or combination of both. Following 24-hour
treatment, cells were fixed and permeabilized (Ba/F3 cells with
paraformaldehyde and methanol; other cells with FIX & PERMH,
Invitrogen), stained with an anti-active caspase-3 PE-conjugated
antibody (BD Biosciences) and analyzed by flow cytometry.
Analysis of DNA content by flow cytometry
Flow cytometric analysis of DNA content using propidium
iodide was performed as previously described [34,35].
Tracking of cell division using carboxyfluorescein
diacetate succinimidyl diester (CFSE) staining
CD34+ cells were stained with 1 mM CFSE (Invitrogen) as
described previously [22,40] and cultured in the presence of
different drug combinations. Total cell viability was assessed using
trypan blue exclusion. Cells cultured with 100 ng/mL colcemid
(Invitrogen) were used to establish the CFSEmax quiescent cell
population at all time points. CFSE+ cells of each condition were
stained with an anti-CD34-APC-conjugated antibody and anti-
active caspase-3-PE-conjugated antibody (BD PharMingen, San
Diego) for quantification of apoptosis. The number of quiescent
cells was determined by measuring the percentage recovery of the
starting number of viable CD34+ cells in the CFSEmax quiescent
subpopulation as described previously [21].
Sample preparation and microarray gene expression
profiling
Microarray gene expression profiling experiments were per-
formed on cell culture triplicates for the parental Ba/F3-p210 cell
line and for two independent Danusertib-resistant clones,
respectively. Total RNA was extracted from frozen cell pellets
(8–106106 cells for each cell culture replicate) using the RNeasy
Mini Kit (Qiagen, Hilden, Germany), after homogenization with
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QIAshredder columns (Qiagen), according to the manufacturer’s
instructions. Biotin-labeled, fragmented cRNA probes were
prepared starting from 1.5 mg of total RNA per replicate sample,
using the ‘One-Cycle Target Labeling and Control Reagents’
(Affymetrix, Santa Clara, CA) according to the protocols by
Affymetrix GeneChip Expression Analysis Technical Manual.
Samples were hybridized onto Affymetrix GeneChipH Mouse
Genome 430A 2.0 arrays (representing approximately 14000 well-
characterized mouse genes) and processed as per manufacturer’s
instructions using ‘GeneChipH Hybridization, Wash, and Stain
Kit’ components (Affymetrix; www.affymetrix.com). Microarray
data analysis was performed using Bioconductor libraries (www.
bioconductor.org). Probe set intensity were calculated using the
RMA algorithm and normalized by the quantile method [41,42].
LIMMA statistical analysis was performed in order to identify
differentially expressed probe sets (pV,0.05, FC.2). Annotation
and functional analysis were performed using Ingenuity Pathways
Analysis (IPA) 7.1 software (IngenuityH System; www.ingenuity.
com), a commercial database containing manually annotated data
for human protein-protein and functional interactions derived
from the literature.
Pharmacological inhibition of Abcg2-mediated resistance
to Danusertib
Cells from two Abcg2-positive and one Abcg2-negative
Danusertib-resistant clones were plated in 24-well plates
(0.36106/well) and treated for 24 hours with different concentra-
tions of Danusertib (0.15–5 mM) in the absence or presence of
5 mM FTC. After fixation and permeabilization, cells were tested
for apoptosis induction and changes in CrkL-phosphorylation
status.
Cloning of murine Abcg2 and retroviral transduction
procedure
Murine Abcg2 was PCR-cloned from the mouse Abcg2 cDNA
clone (Origene, Rockville, USA) into the MSCV-puro-vector
system (Clontech, Moutain View, USA). Retroviral supernatant
was generated using ecotropic Phoenix cells (ATCC, Manassas,
USA) cultured in Dulbecco’s Modified Eagle’s Medium (DMEM,
Invitrogen) supplemented with 10% FBS. Ba/F3 and Ba/F3-p210
cells were transduced with Abcg2-puro or the corresponding
empty-vector using a calcium phosphate transfection protocol.
Briefly, 20 mg DNA were mixed with 62.5 ml 2 M CaCl2 and
adjusted to 500 mL with sterile H2O. 500 mL Hepes-buffered
saline (26 HBS) was slowly added to the DNA solution under
constant air agitation. Afterwards, the solution was mixed with
medium, including 25 mM chloroquine and added to ,66106
Phoenix cells. After incubation over night, medium was replen-
ished to collect virus supernatant after 24, 36 and 48 hours
and supplemented with 4 mg/mL polybrene. After transduction,
cells were selected with puromycin at a final concentration of
2.5 mg/mL.
Supporting Information
Figure S1 Danusertib induces apoptosis, accumulation
of cells with more than or equal to 4N DNA content and
G2/M arrest in BCR-ABL-positive CD34+ cells. CD34+
cells were exposed for 72 hours to indicated concentrations of
Danusertib with (lower panels) or without (upper panels) 1 mM
IM. Analysis of cell cycle and apoptotic/necrotic fraction of
propidium iodide-stained cells was assessed by flow cytometry.
(TIF)
Figure S2 The frequency and mutational spectrum
observed in IM-resistant clones. Exposure to 2 mM (i.e.
56IC50) and 4 mM (i.e. 106IC50) resulted in 47 and 7.3% resistant
clones, respectively. Mutations found in the ABL kinase domain
had already been detected in IM-treated patients, with the
exception of the A424T mutation.
(TIF)
Figure S3 Danusertib resistant cells do not show cross
resistance to IM. Cells from different Danusertib-resistant
clones, cultivated under resistance generating conditions, were
exposed to 5 mMDanusertib or IM for 24 hours. Intracellular flow
cytometric analysis was used to determine CrkL phosphorylation
status.
(TIF)
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